Genital Diseases, Female  >>  sorafenib  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sorafenib / Generic mfg.
NCT00522301: Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission

Terminated
2
6
US
sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Bayer
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
03/08
03/08
NCT00791778 / 2008-004429-41: Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer

Checkmark Maintenance therapy in front line ovarian cancer
Apr 2013 - Apr 2013: Maintenance therapy in front line ovarian cancer
Completed
2
246
Japan, US, Canada, Europe, RoW
Sorafenib (Nexavar, BAY43-9006), Placebo
Bayer
Ovarian Neoplasms
07/11
12/12
NCT00390611: Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer

Completed
2
85
US
Sorafenib, BAY 43-9006, Paclitaxel, Carboplatin
SCRI Development Innovations, LLC, Bayer
Ovarian Cancer
07/12
04/14
NCT00526799: Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer

Terminated
1/2
30
US
Sorafenib, Topotecan
Daniela Matei, MD, Bayer, Hoosier Cancer Research Network
Ovarian Cancer
01/10
08/10
NCT00510250: A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer

Completed
1/2
13
Canada
Sorafenib, Cisplatin, Radiation
University Health Network, Toronto, Bayer
Cancer of the Cervix
09/10
07/15

Download Options